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ABSTRACT 
Aims and objectives: 
 The principal objective of this study was to estimate the plasma levels of 
neutrophil gelatinase associated lipocalin (NGAL) in a cohort of patients with acute 




 NGAL has been studied in the past as a sensitive indicator of acute kidney 
injury and contrast induced nephropathy. Very recently some studies have indicated 
the possibility of elevated NGAL levels in various cardiac conditions with or without 
acute kidney injury. One such study has looked at this molecule in patients with ST 
elevation myocardial infarctions where they found elevated levels in these patients, as 
well as, prognostic benefit of the molecule. 
 
Methods: 
 87 patients with acute coronary syndromes were included in the study. Apart 
from the routine work up and management, all patients underwent determination of 
plasma NGAL and serum high sensitivity C reactive protein (HSCRP) levels at 
admission. The patients were followed up through the hospital stay as well as for one 
month after discharge for clinical outcomes, conventional echocardiographic 
parameters of left ventricular ejection fraction and global longitudinal strain by 
speckle tracking imaging. Plasma NGAL was studied for its predictive power for 




 Plasma NGAL levels were detectably elevated in 67% of patients with acute 
coronary syndromes without any significant proportion with renal dysfunction, sepsis 
or overt infection. Plasma NGAL was the strongest independent predictor of all cause 
hospital mortality in Cox regression multivariate analysis with an odds ratio of 8.353, 
p= 0.0237. Plasma NGAL did not correlate with HSCRP, severity of coronary artery 
disease or major adverse cardiac events at one month follow up. 
 
Conclusion: 
 This is a small study that shows that plasma NGAL in patients admitted with 
acute coronary syndromes, can predict hospital mortality and forms the basis for 
consideration of this molecule as a possible new risk marker in acute coronary 
syndromes meriting further and more extensive investigation. 
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